News

Video: Bionews’ Social Media Campaign Highlights #WhatMakesMeRare

In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…

Fish Model of ALS Links TDP-43 Protein Clumping to Motor Neuron Ills

A zebrafish model that reproduces key amyotrophic lateral sclerosis (ALS) symptoms and characteristics, including protein clumping, when exposed to blue light could aid in understanding disease mechanisms and in developing new treatments. The model was described in the study, “Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related…

Project ALS, Medidata Join to Speed Personalized ALS Therapies

The Medidata Institute and Project ALS have announced a research partnership aimed at better understanding amyotrophic lateral sclerosis (ALS) and developing new and personalized treatment approaches. With a focus on rare diseases, the institute works with scientists, regulatory agencies, patient advocates, life science companies, and research…

Monkeys on Neurotoxic Diet May Be New Animal Model for ALS Research

A neurotoxic amino acid called β-N-methylamino-L-alanine (BMAA) fed to vervet monkeys caused damage to the spinal cord similar to what is seen in amyotrophic lateral sclerosis (ALS), potentially making them a much-needed new animal model for research, a study reported. Adding L-serine, a non-toxic amino acid, to their diet…

Aiforia and NeuroScience Associates Partner to Study Brain Changes in ALS

Aiforia Technologies and NeuroScience Associates (NSA Labs) are collaborating in an effort to learn more about how amyotrophic lateral sclerosis (ALS) affects brain function. The project leverages NSA Lab’s neuroscience expertise and Aiforia’s artificial intelligence (AI) know-how. It came about after the donation of the entire…